Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Periodic limb movements in sleep and cerebral small vessel disease progression: a prospective cohort study].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2023
Same author

Triple anterior chamber after creation of a mixed type-1 and type-2 big bubble during a deep anterior lamellar keratoplasty (DALK): Anterior segment optical coherence tomography (AS-OCT) image.

Journal francais d'ophtalmologie·2019
Same author

[The acute tetraparesis as a rare presentation of Chiari malformation].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2017
Same author

[Disclosure of a mental disorder in the workplace and work accommodations: two factors associated with job tenure of people with severe mental disorders].

L'Encephale·2014
Same author

Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters.

Cancer gene therapy·2014
Same author

Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models.

British journal of cancer·2014

Related Experiment Video

Updated: Jun 11, 2026

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

A fully replication-competent adenovirus vector with enhanced oncolytic properties.

K Toth1, M Kuppuswamy, E V Shashkova

  • 1Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St Louis, MO 63104, USA.

Cancer Gene Therapy
|July 3, 2010
PubMed
Summary

INGN 007, an oncolytic adenovirus vector, demonstrated superior tumor suppression and increased survival in preclinical models. This engineered adenovirus shows promise for enhanced clinical efficacy against various cancers.

More Related Videos

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
14:55

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors

Published on: December 3, 2013

Related Experiment Videos

Last Updated: Jun 11, 2026

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
14:55

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors

Published on: December 3, 2013

Area of Science:

  • Oncolytic virotherapy
  • Gene therapy
  • Cancer research

Background:

  • Adenovirus vectors are utilized for cancer treatment.
  • Modifications to adenovirus genes, such as E1A, can alter their oncolytic properties.
  • Overexpression of the Adenovirus Death Protein (ADP) is a strategy to enhance cell lysis.

Purpose of the Study:

  • To compare the oncolytic efficacy of two adenovirus vectors, KD3 and INGN 007, with distinct E1A gene modifications.
  • To evaluate the antitumor activity of these vectors in various preclinical cancer models.
  • To assess the potential of INGN 007 as a superior oncolytic agent compared to existing therapies.

Main Methods:

  • Development of two adenovirus vectors: KD3 (E1A deletions) and INGN 007 (wild-type E1A), both overexpressing ADP.
  • Administration of vectors via intratumoral and intravenous injection in mouse models bearing human tumors (A549, Hep3B, LNCaP).
  • Evaluation of tumor growth suppression, tumor shrinkage/disappearance, and survival rates.
  • Comparison of INGN 007 efficacy against wild-type Ad5 and dl1520 (ONYX-015).

Main Results:

  • Both KD3 and INGN 007 suppressed subcutaneous tumor growth in A549 and Hep3B models after intratumoral injection.
  • Intravenous injection of KD3 and INGN 007 contained LNCaP tumor growth, with some tumors shrinking or disappearing.
  • INGN 007 significantly increased mean survival time (35%) against subcutaneous A549 tumors after intravenous injection, outperforming KD3 and wild-type Ad5.
  • INGN 007 demonstrated efficacy in a challenging A549 orthotopic lung cancer model and was superior to dl1520 against A549 tumors.

Conclusions:

  • INGN 007 exhibits potent oncolytic activity and superior antitumor efficacy compared to KD3, wild-type Ad5, and dl1520 in preclinical models.
  • The wild-type E1A gene in INGN 007, combined with ADP overexpression, contributes to enhanced therapeutic potential.
  • INGN 007 represents a promising oncolytic adenovirus vector for clinical development in cancer therapy.